Quest Diagnostics Incorporated DGX
Composite 59/100; the shares have moved about 24% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 46/100 — a slight mark against it.
Momentum ranks 74/100 — a moderate point in its favour. Growth ranks 70/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Valuation ranks 46/100 — a slight mark against it.
What the company does Quest Diagnostics (DGX) operates a U.S. network of labs and patient centers, delivering diagnostic testing and services under brands like AmeriPath and ExamOne to hospitals, insurers, and employers.
Key financials DGX posts ROE 14.6%, ROA 6.4%, and ROCE 10.9%. Margins: gross 33.2%, operating 15.2%, net 9.2%. Revenue grew 10.2% and EPS 15.0%. Debt/equity is 0.81; interest coverage 6.28 and current ratio 1.59.
Stock health Momentum is strong: +24.08% over 3m, +28.44% over 6m, +39.17% over 12m. RSI(14) is 73.00, indicating overbought conditions. Sideravia scores Quality 53.0, Growth 45.1, Momentum 75.5.
Price vs fair value DGX trades at a discount of 4.30% versus the analyst mean target of 245.87. - Simply Wall St argues DGX may be 32% undervalued as guidance rises (Simply Wall St.) - Simply Wall St also asks if DGX is a bargain following raised guidance and strong quarterly results (Simply Wall St.) - The Wall Street Journal highlights operational challenges in lab technician conditions (The Wall Street Journal)
Looking forward Forward P/E is 21.51 and PEG 1.32, suggesting moderate valuation relative to growth. Analysts see upside if guidance holds, though recent headlines flag operational risks.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.